Hutchison China MediTech Limited (LON:HCM)‘s stock had its “buy” rating reissued by research analysts at Panmure Gordon in a note issued to investors on Friday. They currently have a GBX 2,630 ($34.33) price objective on the stock. Panmure Gordon’s target price points to a potential upside of 44.31% from the company’s previous close.

Separately, Beaufort Securities reissued a “buy” rating on shares of Hutchison China MediTech Limited in a report on Wednesday, August 3rd.

Shares of Hutchison China MediTech Limited (LON:HCM) opened at 1830.00 on Friday. The company’s 50-day moving average price is GBX 1,837.64 and its 200-day moving average price is GBX 1,884.38. The company’s market cap is GBX 1.11 billion. Hutchison China MediTech Limited has a 12 month low of GBX 1,612.50 and a 12 month high of GBX 2,896.60.

In related news, insider Nash,Christopher bought 42 shares of the company’s stock in a transaction on Thursday, August 4th. The shares were purchased at an average price of GBX 1,899 ($24.79) per share, for a total transaction of £797.58 ($1,041.09).

Hutchison China MediTech Limited Company Profile

Hutchison China MediTech Limited (Chi-Med) is a China-based, globally-focused healthcare group. The Company researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the global market.

Receive News & Ratings for Hutchison China MediTech Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hutchison China MediTech Limited and related companies with Analyst Ratings Network's FREE daily email newsletter.